| Mark Charles Nenow, MD | |
|
2010 Garfield Ave, Parkersburg, WV 26101-2526 | |
| (304) 865-5535 | |
| Not Available |
| Full Name | Mark Charles Nenow |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 38 Years |
| Location | 2010 Garfield Ave, Parkersburg, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942247085 | NPI | - | NPPES |
| P000261743 | Other | NC | RAILROAD MEDICARE |
| 5902147 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 200500226 (North Carolina) | Secondary |
| 207Y00000X | Otolaryngology | 29404 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Camden Clark Medical Center | Parkersburg, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Camden-clark Physician Corporation | 5294885661 | 185 |
News Archive
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.
A breakthrough technique that allows scientists to view individually-labeled tumor cells as they move about in real time in a live mouse may enable scientists to develop microenvironment-specific drugs against cancer, researchers report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
| Entity Name | Camden-clark Physician Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710125430 PECOS PAC ID: 5294885661 Enrollment ID: O20090604000570 |
News Archive
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.
A breakthrough technique that allows scientists to view individually-labeled tumor cells as they move about in real time in a live mouse may enable scientists to develop microenvironment-specific drugs against cancer, researchers report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Charles Nenow, MD 321 Mulberry St Sw, Medical Staff Services, Lenoir, NC 28645-5720 Ph: (828) 757-5965 | Mark Charles Nenow, MD 2010 Garfield Ave, Parkersburg, WV 26101-2526 Ph: (304) 865-5535 |
News Archive
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.
A breakthrough technique that allows scientists to view individually-labeled tumor cells as they move about in real time in a live mouse may enable scientists to develop microenvironment-specific drugs against cancer, researchers report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago